Q1 data analysis

It is no understatement to claim that 2018 has kicked off with a bang, setting the stage for what could become one of the most successful years for university venturing. The jaw-dropping $8.7bn acquisition of Ohio State University’s gene therapy developer Avexis by Novartis may be fresh on everyone’s mind, but it happened earlier this…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.